Pharma BD Deal Intelligence
Repare Therapeutics announces worldwide license and collaboration agreement with Roche for camonsertib (RP-3500) ATR inhibitor worth up to $1.325B.
After halting the planned Phase 3 of camonsertib+lunresertib and cutting ~75% of staff, Repare agreed to be acquired by nonprofit XenoTherapeutics.
Form 8-K reporting completion of the plan of arrangement under which XenoTherapeutics / Xeno Acquisition Corp. acquired Repare; final order issued by Superior…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Roche obtained a worldwide license to develop and commercialize camonsertib (RP-3500), Repare's ATR inhibitor targeting cancers with specific DNA damage repair deficiencies (synthetic lethality approach). Roche paid $125 million upfront with up to $1.2 billion in milestone payments. Deal was terminated in February 2024 when Roche returned global rights to Repare, just weeks after a $40 million clinical milestone payment for first patient dosing in the Tapistry Phase II trial. Post-termination, Repare was unable to re-partner camonsertib with another large pharma: it announced a portfolio re-prioritization in January 2025, out-licensed the separate PKMYT1 inhibitor lunresertib (not camonsertib) to Debiopharm in July 2025, and was ultimately acquired by nonprofit XenoTherapeutics, Inc. — a deal completed January 28, 2026 (~US$2.20/share in cash plus a contingent value right) that took Repare private.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Repare Therapeutics Inc. (this deal) | 2022 | $1.3B | 68 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2022 deals · Roche Holding AG deals · Neurology deals